Kiora Pharmaceuticals Valuation
| KPRX Stock | USD 3.18 0.03 0.95% |
At this time, the firm appears to be overvalued. Kiora Pharmaceuticals secures a last-minute Real Value of $2.74 per share. The latest price of the firm is $3.18. Our model forecasts the value of Kiora Pharmaceuticals from analyzing the firm fundamentals such as Shares Outstanding of 3.04 M, return on equity of -0.41, and Operating Margin of (484.21) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Kiora Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Kiora Pharmaceuticals is based on 3 months time horizon. Increasing Kiora Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kiora Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kiora Stock. However, Kiora Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.18 | Real 2.74 | Hype 3.18 | Naive 3.46 |
The intrinsic value of Kiora Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kiora Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kiora Pharmaceuticals helps investors to forecast how Kiora stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kiora Pharmaceuticals more accurately as focusing exclusively on Kiora Pharmaceuticals' fundamentals will not take into account other important factors: Kiora Pharmaceuticals Total Value Analysis
Kiora Pharmaceuticals is now projected to have valuation of (14.27 M) with market capitalization of 9.68 M, debt of 57.17 K, and cash on hands of 2.43 M. The negative valuation of Kiora Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Kiora Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(14.27 M) | 9.68 M | 57.17 K | 2.43 M |
Kiora Pharmaceuticals Investor Information
About 46.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kiora Pharmaceuticals recorded a loss per share of 4.26. The entity last dividend was issued on the 30th of August 2019. The firm had 1:9 split on the 11th of June 2024. Based on the key indicators related to Kiora Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Kiora Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Kiora Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kiora Pharmaceuticals has an asset utilization ratio of 43.91 percent. This suggests that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Kiora Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Kiora Pharmaceuticals Ownership Allocation
30% of Kiora Pharmaceuticals outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.Kiora Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 16.02 M. Net Income was 3.59 M with loss before overhead, payroll, taxes, and interest of (1.21 M).About Kiora Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Kiora Pharmaceuticals. We calculate exposure to Kiora Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kiora Pharmaceuticals's related companies.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Kiora Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.1 M | |
| Forward Price Earnings | 2.4102 |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.